Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Equity (2016 - 2025)

Sunshine Biopharma's Return on Equity history spans 12 years, with the latest figure at 0.05% for Q4 2025.

  • For Q4 2025, Return on Equity changed 0.0% year-over-year to 0.05%; the TTM value through Dec 2025 reached 0.05%, changed 0.0%, while the annual FY2025 figure was 0.05%, 1.0% down from the prior year.
  • Return on Equity reached 0.05% in Q4 2025 per SBFM's latest filing, up from 0.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 25.85% in Q4 2021 to a low of 1.33% in Q1 2023.
  • Average Return on Equity over 5 years is 2.37%, with a median of 0.11% recorded in 2022.
  • Peak YoY movement for Return on Equity: skyrocketed 926bps in 2021, then plummeted -2671bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 25.85% in 2021, then tumbled by -103bps to 0.86% in 2022, then soared by 76bps to 0.21% in 2023, then surged by 127bps to 0.06% in 2024, then dropped by -7bps to 0.05% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Return on Equity are 0.05% (Q4 2025), 0.02% (Q3 2025), and 0.01% (Q2 2025).